Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma;La TSH humana recombinante en el seguimiento de pacientes con cáncer diferenciado de tiroides

Revista Espanola de Medicina Nuclear

Volumn 22, Issue 5, 2003, Pages 295-305

  Gomez Camarero P ^a,b   Martinez Brocca M A ^a   Rodriguez Rodriguez J R ^a   Navarro Gonzalez E ^a   Tirado Hospital, J L ^a   Gonzalez Duarte D ^a   Vazquez Albertino R ^a   Astorga Jimenez, R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b s/n ^*  (Spain)

Author keywords

Differentiated thyroid cancer; Radioiodine scan; Recombinant human thyrotropin; Thyroglobulin blood

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; MALE; PAPILLARY CARCINOMA; RADIODIAGNOSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; BLOOD; BONE TUMOR; CASE REPORT; CELL DIFFERENTIATION; EVALUATION; IMMUNOLOGY; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AUTOANTIBODIES; BONE NEOPLASMS; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 0642375019     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13052230     Document Type: Article

References (26)

1. Parkin DM, Muir CS, Whelan SL, Gao YT, Powell JF. Cancer incidence in five continents. Vol VI. Lyon. IARC Scientific Publications 1992; p. 120.
2. Durán M, Monereo S, Pavón I, Vega B, Elviro R. Tasa de incidencia de cáncer de tiroides en la zona Sur de Madrid. Endocrinología 1998;45:179-82.
3. Alcázar V, Mondéjar BM, Del Val TL, De Icaya PM, Del Olmo D, Jaunsolo MA, et al. Tasa de incidencia y características del cáncer de tiroides en un área de la zona sur de Madrid. Endocrinología 2000;47:182-84.
4. Fahey TJ III, Reves TS, Delbridge L. Increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg 1995;82:518-20.
5. Ries LAG, Eisner MP, Kosary CL. 2000 SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute.
6. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
7. Mazzaferri E. An overview of the managment of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.
8. Ozata M, Suzuki S, Miyamoto T, Liu R, Fierro-Renoy F, De-Groot L. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
9. Mazzaferri E. NCCN thyroid carcinoma practice guidelines. Oncology 1999;13:391-442.
10. Hassey-Dow K, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9.
11. Schlumberger M, Charbord P, Fragu P, Gardet P, Lumbroso JD, Parmentier C, et al. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. JCEM 1983;57:148-51.
12. Melmed S, Harada A, Hershman JM, Krishnamurthy GT and Blahd WH. Neutralizing antibodies to bovine thyrotropin in inmunized patients with thyroid cancer. JCEM 1980;51:358-63.
13. Law A, Jack GW, Tellez M, Edmonds CJ. In-vivo studies of a human thyrotropin preparation. J Endocrinol. 1986;110:375-8.
14. Braverman LE, Pratt BM, Ebner S, Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992;74:1135-9.
15. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ros DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma. JCEM 1994;78:188-96.
16. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. N Engl J Med 1997;337:888-896.
17. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
18. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-25.
19. Ringel MD and Ladenson PW. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996;81:1724-5.
20. Luster M, Lassamann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000;85:3640-5.
21. Rodríguez JR. La TSH humana recombinante (rhTSH) en el control y seguimiento de los pacientes con cáncer diferenciado de tiroides: más cerca del objetivo. Rev Esp Med Nuclear 1999;18:401-7.
22. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-51.
23. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radiodiodine theraphy: case report and review of the literaturre. Endocr Pract 2000;6:460-4.
24. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999;22(Suppl 11):30-4.
25. Nijhuis TF, van Weperen W and de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999;21:98-100.
26. Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. European Journal of Endocrinology, 2000;143:557-63.